| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Mibavademab | REGN-4461 | Phase 3 Clinical | Lipodystrophy, Congenital Generalized; Lipodystrophy, Familial Partial; Obesity; Lipid Metabolism Disorders | Details | |
| ERX-1000 | ERX-1000 | Phase 1 Clinical | ERX Pharmaceuticals Inc | Obesity | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Metreleptin | KTR-103; AC-164594 | Approved | Amylin Pharmaceutical, Bristol-Myers Squibb Company, Astrazeneca Plc | Metreleptin [SHIONOGI], Myalepta | Japan | Lipodystrophy | Shionogi & Co Ltd | 2013-03-25 | HIV Infections; Diabetes Mellitus, Type 1; Metabolic Dysfunction-Associated Steatotic Liver Disease; Insulin Resistance; Metabolic Syndrome; Lipodystrophy; Obesity; Lipodystrophy, Congenital Generalized; Lipodystrophy, Familial Partial; Lipomatosis, Multiple Symmetrical; Overweight; Diabetes Mellitus; Hyperlipidemias | Details |




